
    
      To determine the safety and efficacy (viral load suppression and cluster of differentiation 4
      [CD4] changes) of a simple, once-daily (QD) antiretroviral (ARV) regimen consisting of a
      fixed-dose combination tablet containing Truvada combined with the protease inhibitor
      atazanavir (ATV) boosted with ritonavir (ATV/r).

      To evaluate fasting glucose, insulin, C peptide and lipid panel (total cholesterol, high and
      low density lipoprotein cholesterol (HDL, LDL), and serum triglycerides) in subjects
      receiving Truvada and boosted atazanavir.

      To evaluate adherence to a QD ARV regimen of Truvada and boosted atazanavir.

      To evaluate steady-state plasma pharmacokinetics (PK) of Truvada and atazanavir in study
      subjects receiving Truvada and boosted atazanavir.
    
  